Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Non-small cell lung cancer (NSCLC) (closed to accrual as of 8/9/07) meeting 1 of
the following stage criteria:

- Stage IIIB disease

- Patients without pleural effusion who are not candidates for combined
modality treatment OR who were treated at centers where combined
modality treatment is not considered standard treatment are eligible

- Stage IV disease

- Local or metastatic failure after prior surgery and/or radiotherapy

- Colorectal cancer

- Metastatic disease

- Considered suitable for first-line therapy with capecitabine

- Other tumor types

- Suitable for treatment with capecitabine

- No more than 2 prior chemotherapy regimens for advanced or metastatic
disease

- Incurable by radiotherapy or surgery

- Clinically or radiologically documented disease

- No tumor marker elevation as the only evidence of disease

- No necrotic or hemorrhagic tumor or metastases

- No untreated brain or meningeal metastases

- Patients with previously treated stable brain metastases (by radiography or
clinical exam) are eligible provided they are asymptomatic and do not require
corticosteroids

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- At least 12 weeks (colorectal cancer patients)

Hematopoietic

- Hemoglobin adequate

- Anemia allowed provided patient is well compensated with no evidence of recent
bleeding

- Absolute granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No overt bleeding (i.e., ≥ 30 mL/episode) within the past 3 months

Hepatic

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT or AST ≤ 2 times ULN (5 times ULN for documented liver metastases)

Renal

- Creatinine ≤ 1.5 times ULN OR

- Creatinine clearance ≥ 50 mL/min

- No proteinuria > grade 1

Cardiovascular

- Resting systolic blood pressure ≤ 150 mm Hg AND/OR resting diastolic blood pressure ≤
100 mm Hg (in the presence or absence of a stable dose of antihypertensive
medication)

- Mean QTc ≤ 470 msec (with Bazetts correction) by ECG

- LVEF > 50% for patients with prior anthracyclines/trastuzumab or cardio-toxic agents

- No untreated or uncontrolled cardiovascular condition

- No symptomatic cardiac dysfunction

- No poorly controlled hypertension

- No history of labile hypertension

- No history of poor compliance with antihypertensive medication

- No history of familial long QT syndrome

Pulmonary

- No clinically relevant hemoptysis (i.e., ≥ 5 mL fresh blood) within the past 4 weeks

- Patients with only flecks of blood in their sputum are eligible

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective (double-method for females; barrier method for
males) contraception

- No prior allergic reaction to drugs containing Cremophor EL® (NSCLC patients [closed
to accrual as of 8/9/07])

- No peripheral neuropathy > grade 1 (NSCLC patients [closed to accrual as of 8/9/07])

- No dihydropyrimidine dehydrogenase deficiency (colorectal cancer patients)

- No history of severe hand-foot syndrome after treatment with fluoropyrimidines
(colorectal cancer patients)

- No other malignancy within the past 5 years except adequately treated nonmelanoma
skin cancer or other curatively treated solid tumor

- No active or uncontrolled infection

- No other serious illness or medical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No prior antiangiogenesis therapy

Chemotherapy

- At least 4 weeks since prior single-agent non-platinum-containing chemotherapy (6
weeks for nitrosoureas or mitomycin) for metastatic disease (NSCLC patients [closed
to accrual as of 8/9/07])

- No more than 1 prior single-agent non-platinum-containing chemotherapy regimen
for metastatic disease

- At least 6 months since prior adjuvant or neoadjuvant chemotherapy

- No prior taxane therapy (NSCLC patients [closed to accrual as of 8/9/07])

- No prior chemotherapy for metastatic disease (colorectal cancer patients)

- No prior capecitabine (colorectal cancer patients)

Endocrine therapy

- See Disease Characteristics

- At least 4 weeks since prior corticosteroids

Radiotherapy

- See Disease Characteristics

- At least 21 days since prior palliative radiotherapy except for low-dose
non-myelosuppressive radiotherapy with approval

- At least 6 months since prior adjuvant radiotherapy

Surgery

- See Disease Characteristics

- At least 14 days since prior major surgery

Other

- Recovered from prior therapy

- At least 14 days since prior epidermal growth factor receptor inhibitor therapy

- Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is strictly
monitored

- No other concurrent investigational therapy

- No other concurrent anticancer therapy

- No concurrent prophylactic pyridoxine (vitamin B_6) for hand-foot syndrome
(colorectal or other tumor type patients)

- Use of pyridoxine after the onset of hand-foot syndrome allowed at the
discretion of the physician